May 22nd 2025
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Watch the series now!
Careful Observation of Ovarian Cysts Safe Alternative to Surgery
Dr Sibel Blau Discusses the Role of the Quality Cancer Care Alliance